ABCD is pleased to announce the updated guidance on SGLT-2 inhibitors in type 2 diabetes. SGLT-2 inhibitors are being used increasingly not only for better diabetes control with less risk of hypoglycaemia and favourable weight loss, but also for their cardiovascular and renal benefits in people with and without diabetes. It is hoped that the updated guidance will help non-specialists to use SGLT-2 inhibitors safely and in the right patients for maximum benefit.
Date of Announcement:
Image: Professor Umesh Dashora
Consultant
